Aromatic sulfone hydroxamic acids and their use as protease inhibitors

US6683093B2 · kind B2 · utility

Assignee

• Pharmacia Corporation · SE

Inventors

• Thomas E. Barta · Evanston, US
• Daniel P. Becker · Glenview, US
• Louis Bedell · Rantoul, US
• Terri Boehm · Ballwin, US
• Jeffery Carroll · Columbia, US
• Gary A. DeCrescenzo · Holden, US
• Yvette M. Fobian · Labadie, US
• John N. Freskos · Clayton, US
• Daniel P. Getman · Chesterfield, US
• Joseph McDonald · Ballwin, US
• Madeleine Li · Vernon Hills, US
• Susan L. Hockerman · Kirkwood, US
• Carol Howard · Fenton, US
• Steve Kolodziej · Ballwin, US
• Deborah A. Mischke · Defiance, US
• Joseph G. Rico · Ballwin, US
• Nathan Stehle · Ballwin, US
• Michael B. Tollefson · Dardenne Prairie, US
• William Vernier · Chesterfield, US
• Clara I. Villamil · Glenview, US
• Darren Kassab · Wildwood, US

Key dates

• Filing date: Nov 21, 2001
• Grant date: Jan 27, 2004
• Expiry date: Nov 21, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.